Page 41 - Jack Bailey News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Several of these recommended books on the Chisholm Trail are available for free online. Writers and readers can’t get enough stories about those 1800s cattle trails. As you read this, I am out of the office. Yet I did not forget the statewide readership of the Think, Texas newsletter and column. In my absence, allow me to offer an Aug. 20, 2017, column about the Chisholm Trail written by my colleague Glen Seeber of the Oklahoman, a sibling Gannett newspaper in the USA Today Network. While there are many books about the cattle drives of the late 1800s and the mostly young men who faced the d...

February 17, 2021 7:38 PMGayVN - By SAN FRANCISCO—NakedSword Originals has released the first episode of its second feature of 2021, Lake Need, starring popular gay performer Johnny Rapid. In this episode, Rapid rounds up all his best buds and heads to Lake Need for a boy’s trip, but beyond the serene waters, there's nonstop bareback action on deck in this sun-drenched adventure now playing only on NakedSword.com. Director Edward James is the captain of a houseboat on Lake Need that's populated by a cast of horny studs who just want to get off with their best buds. The new series will ...

by Barry Teater, NCBiotech writer — February 16, 2021 . RESEARCH TRIANGLE PARK – After 13 years as a clinical-stage oncology company, G1 Therapeutics of Research Triangle Park transformed into a commercial-stage company overnight upon the approval of its first drug by the U.S. Food and Drug Administration. The FDA on Feb. 12 approved G1’s trilaciclib, to be marketed as Cosela, for protecting bone marrow from chemotherapy damage in adult patients with extensive-stage small cell lung cancer (ES-SCLC). “Cosela will help change the chemotherapy experience for people who are battling ES...

The FDA approved G1's Cosela on Friday. (FDA) Despite the ever-growing use of targeted oncology drugs, chemotherapy is still widely used in lung cancer—and it still comes with potentially severe side effects. G1 Therapeutics just won FDA approval for a therapy that can help combat one of the most serious. G1's Cosela scored a green light to reduce the bone marrow damage that can come along with chemo. Given ahead of certain chemotherapy regimens to patients with extensive-stage small-cell lung cancer, Cosela is the first medicine designed for that purpose. As the biotech points out, ch...

  After 13 years as a clinical-stage oncology company, G1 Therapeutics of Research Triangle Park transformed into a commercial-stage company overnight upon the approval of its first drug by the U.S. Food and Drug Administration. The FDA on Feb. 12 approved G1’s trilaciclib, to be marketed as Cosela, for protecting bone marrow from chemotherapy damage in adult patients with extensive-stage small cell lung cancer (ES-SCLC).  “Cosela will help change the chemotherapy experience for people who are battling ES-SCLC,” said Jack Bailey, the company’s chief executive officer. “G1 is prou...